account_id none on file
legal_name Black Diamond Therapeutics, Inc.
ticker BDTX
cik 1701541
domain blackdiamondtherapeutics.com
linkedin_company_url https://www.linkedin.com/company/black-diamond-therapeutics/
entry_point_account_id none on file
name Black Diamond Therapeutics Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 4 executives 0 family 0
why_nownone on file
callsnone on file
filings
In addition, personnel expenses decreased by $0.4 million as we continue to capitalize on workforce efficiencies and focus on our development program, and facilities expenses decreased by $0.4 million due to the sublease of the remaining floor of our Cambridge, Massachusetts office space in December 2025.
filing / Aug 5, 2026 / receipt
In addition, personnel expenses decreased by $0.7 million as we continue to capitalize on workforce efficiencies and focus on advancing and optimizing development for silevertinib, and facilities expenses decreased by $0.9 million due to the sublease of the remaining floor of our Cambridge, Massachusetts office space in December 2025.
filing / Aug 5, 2026 / receipt
In addition, personnel expenses decreased by $0.4 million as we continue to capitalize on workforce efficiencies and focus on advancing and optimizing development for silevertinib, and facilities expenses decreased by $0.4 million due to the sublease of the remaining floor of our Cambridge, Massachusetts office space in December 2025.
filing / May 7, 2026 / receipt
On December 5, 2025, the Company entered into a sublease for the remaining floor of its Cambridge, Massachusetts office space.
filing / May 7, 2026 / receipt
executivesnone on file
familynone on file
upcoming
| 2026-11-05 | earnings call | scheduled | ir |
changes
| 2021-11-22 | Chief Financial Officer, departed | sec_8k |
mcp_package_hint
slug black-diamond-therapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$